Edgewise Therapeutics
Watchlist
Edgewise Therapeutics (EWTX): Billion-Dollar Potential in the Fight Against Muscle Diseases. Scotiabank Sees 75% Upside Potential.
Reading Time: 2 minutes
The stock of Edgewise Therapeutics (EWTX) could end its consolidation on Friday. It is a biopharmaceutical company focused on developing novel therapies for the treatment of severe muscle diseases. The company utilizes its scientific insights and technological platforms to develop small molecules specifically aimed at modulating muscle biology. Edgewise Therapeutics' therapies are designed to improve muscle strength and function in patients with genetic muscle diseases and other muscle disorders. Duchenne and Becker muscular dystrophy are...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
